logo
Hibernation's Hidden Healing ‘Superpowers' Could Be Locked in Our DNA

Hibernation's Hidden Healing ‘Superpowers' Could Be Locked in Our DNA

Gizmodo4 days ago
After spending months without eating, drinking, or moving, hibernating mammals must rebound from extreme physiological changes. Two new studies suggest that the genetic 'superpowers' underlying this incredible resilience may also be present in the human genome.
For these studies, published Thursday, July 31, in the journal Science, researchers at the University of Utah honed in on the specific DNA regions that help hibernators rapidly recover from muscle atrophy, insulin resistance, and brain damage. They found strong evidence to suggest that the human genome shares these genetic regions, which function as control switches for hibernator adaptations. Finding and harnessing them could lead to new treatments for type 2 diabetes, Alzheimer's disease, and other disorders, the researchers say.
'Humans already have the genetic framework,' said Susan Steinwand, a neurobiology and anatomy researcher at U of U Health and first author of one of the studies. 'We just need to identify the control switches for these hibernator traits.'
During hibernation, mammals enter a state of torpor, or physiological dormancy. This allows them to survive months without food and water, but at great cost to their health. Their muscles deteriorate due to lack of nutrition and movement, Christopher Gregg, a professor of neurobiology at U of U and senior author on both studies, told Gizmodo. Proteins associated with Alzheimer's disease build up in their brains, and upon awakening, the sudden reperfusion of blood can cause further neurological damage, he explained. What's more, they become insulin resistant due to the amount of fat they gain to sustain them during months of starvation.
Hibernating mammals have evolved remarkable adaptations to reverse this extensive physiological damage. The genes that underlie these adaptations are likely also present in humans and other non-hibernators, Gregg explained. The fact that hibernation has evolved independently in multiple animal species suggests that its basic genetic ingredients are present across the mammalian genome. Therefore, non-hibernators may still carry them.
'We mostly all have the same genes across species,' Gregg said. 'The big change is in the 98% of the genome that does not encode for genes.' Non-coding DNA is largely responsible for gene regulation. In hibernators, specific regions of non-coding DNA act as 'master switches' for controlling functional gene responses to starvation and refeeding, he explained.
Finding these master switches in the mammalian genome is like searching for needles in a DNA haystack. To accomplish this, the researchers made whole-genome comparisons across mammals to identify conserved DNA regions that are stable in most species but show accelerated change in hibernators. These hibernator-accelerated regions are regulators that turn genes on in specific cells at specific times, Elliott Ferris, a data analyst in Gregg's lab at U of U and first author of one of the studies, told Gizmodo.
To understand the biological processes that may be linked to these hibernator-accelerated regions, the researchers identified genes that get turned up or turned down during fasting in mice. Hibernation is an adaptation to survive food scarcity, so fasting triggers similar metabolic changes. This led them to 'hub genes' that act as master regulators for fasting-induced changes to gene activity.
'The really surprising discovery that was very exciting was that the hibernation-linked elements are disproportionately affecting those key hub genes,' Gregg explained. 'The implication is that hibernators changed the regulation and activity of these core hub genes to have big downstream effects on the whole program for responding to food scarcity and food deprivation. That's important as we think about translating this knowledge into the real world.'
Gregg is co-founder of Primordial AI, a Utah-based biotech startup that leverages AI to uncover master regulator gene drug targets. Through this company, he aims to develop drugs that mimic the genetic advantages hibernators have, such as boosting neuroprotection in Alzheimer's patients or reversing insulin resistance in type 2 diabetics. 'Those hub genes are the ones that we think are a really good starting point to design medicines to affect those genes,' Gregg said.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

John Gleeson, attorney and resilient polio survivor, dies at 86
John Gleeson, attorney and resilient polio survivor, dies at 86

Yahoo

time24 minutes ago

  • Yahoo

John Gleeson, attorney and resilient polio survivor, dies at 86

The polio that afflicted him as a boy never left John Gleeson, but it never held him back. "He's someone who just never let anything bring him down," Gerry Gleeson II said Saturday, July 26, adding that the disease essentially paralyzed his father for two years of his childhood. Polio caused some life-long mobility challenges — though no one could blame the disease for Gleeson's penchant for wearing black Gold Toe socks with shorts — but it also contributed to a resiliency that made an impression on his family. "There was no obstacle — nothing was going to hold him back from whatever he was going to achieve," his son said. Gleeson, who earned a law degree at night while working as a teacher, became a beloved raconteur known for welcoming a constellation of engaging conversationalists into his West Bloomfield home long before he died July 18 at the age of 86. While Gleeson loved being a lawyer — "he liked the intellectual challenge, he liked being in court, he liked being before a jury," his son said — he also loved holding court at home. Gleeson and his wife Mary Ellen, who died in 2018, hosted dinner gatherings in which the conversation flowed along with fine wine. "In addition to all his other fine qualities, he was a wine connoisseur," said Steve Fishman, a prominent defense attorney who got to know him through Gerry Gleeson who, like his father, became an attorney. Gleeson, Fishman said, had "an unbelievable wine cellar." The Gleesons' passion for the grape led them to spend many winters in Napa Valley, the region in northern California known for hundreds of vineyards. Gleeson, known to his granddaughters as "Papa," also savored spending time with family. Gerry Gleeson said that even though his father was a "fiercely competitive" attorney (he specialized in environmental law and represented businesses), "he'd make a point to be home early to be with family." Even though Gleeson favored the conservative Fox News network, his experience with polio made him an early proponent of the COVID-19 vaccine, his son said, adding that his dad was "first in line" when it became available. Reflecting on his father's life and the time they spent together, Gerry Gleeson said one of the things he'll miss most is "sitting around the grill shooting the breeze." Gleeson's survivors include son John and granddaughters Madeleine, Sydney and Margaux. Visitation will be Monday, July 28 from 9 a.m. to 10 a.m. at Holy Name Catholic Church, 630 Harmon, Birmingham, followed by a funeral mass at 10 a.m. M.L. Elrick is a Pulitzer Prize- and Emmy Award-winning investigative reporter, director of student investigative reporting program Eye On Michigan, and host of the ML's Soul of Detroit podcast. Contact him at mlelrick@ or follow him on X at @elrick, Facebook at ML Elrick and Instagram at ml_elrick. This article originally appeared on Detroit Free Press: John Gleeson, attorney and resilient polio survivor, dies at 86 Solve the daily Crossword

FDA approves SetPoint's neuroimmune modulation device for RA treatment
FDA approves SetPoint's neuroimmune modulation device for RA treatment

Yahoo

time32 minutes ago

  • Yahoo

FDA approves SetPoint's neuroimmune modulation device for RA treatment

The US Food and Drug Administration (FDA) has approved SetPoint Medical's implantable neuroimmune modulation device, SetPoint System, to treat moderate-to-severe rheumatoid arthritis (RA) in adults. The system is designed for individuals who are inadequately managed by or intolerant to current RA therapies such as biological and targeted synthetic disease-modifying anti-rheumatic drugs (DMARDs). The system is said to activate the body's natural anti-inflammatory and immune-restorative pathways by delivering electrical stimulation to the vagus nerve once a day. The neurostimulation therapy can potentially provide an alternative treatment without immune-compromising risks. The FDA approval was based on the outcomes of the RESET-RA study, a 242-patient double-blind, randomised, sham-controlled trial, which showed the system's efficacy and safety in this patient group. Patients tolerated the device placement procedure and the stimulation therapy well, with a low incidence of related serious adverse events at 1.7%. SetPoint Medical CEO Murthy Simhambhatla said: 'The approval of the SetPoint System, the first-in-class neuroimmune modulation platform, represents a transformative milestone in the management of autoimmune diseases. 'We are committed to improving the health of people living with RA, and look forward to working with providers and payers to make our innovative therapy accessible to their patients. We plan to introduce the SetPoint System in targeted US cities this year, followed by expansion across the country starting in early 2026.' SetPoint Medical is also exploring the use of its neuroimmune modulation platform for other autoimmune diseases such as multiple sclerosis (MS) and Crohn's disease. In March 2024, the company's neuroimmune modulation device secured a breakthrough device designation to treat relapsing-remitting MS. "FDA approves SetPoint's neuroimmune modulation device for RA treatment" was originally created and published by Medical Device Network, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Sign in to access your portfolio

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store